Long-term evaluation of opioid treatment in fibromyalgia

Clinical Journal of Pain

Volumn 31, Issue 1, 2015, Pages 7-13

  Peng, Xiaomei ^a   Robinson, Rebecca L ^a   Mease, Philip ^e,f,g   Kroenke, Kurt ^b,c   Williams, David A ^h   Chen, Yi ^d   Faries, Douglas ^a   Wohlreich, Madelaine ^a   McCarberg, Bill ⁱ   Hann, Danette ^j  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c REGENSTRIEF INSTITUTE   (United States)

^d PharmaNet/i3   (United States)

^e Seattle Rhumatology Associates   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ KAISER PERMANENTE   (United States)

^j SYNEOS HEALTH   (United States)

more..

Author keywords

fibromyalgia; observational; opioids; outcomes

Indexed keywords

BEZITRAMIDE; BUPRENORPHINE; BUTORPHANOL; CODEINE; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE NAPSILATE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS PENTAZOCINE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; GENERALIZED ANXIETY DISORDER SCALE 7; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; INSOMNIA SEVERITY INDEX; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PAIN SEVERITY; PATIENT HEALTH QUESTIONNAIRE 8; PRIMARY MEDICAL CARE; PROPENSITY SCORE; SHEEHAN DISABILITY SCALE; COHORT ANALYSIS; COMPLICATION; DEPRESSION; OBSERVATION; PAIN MEASUREMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUESTIONNAIRE; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME; TREATMENT OUTCOME;

ADULT; ANALGESICS, OPIOID; COHORT STUDIES; DEPRESSION; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TRAMADOL; TREATMENT OUTCOME;

EID: 84918830845     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0000000000000079     Document Type: Article

References (30)

1. Bogetto F, Bonatto Revello R, Bertoli C, et al. Fibromyalgia: psychopathologic aspects. Minerva Psichiatr. 1999;40:129-138.
2. Hudson JI, Goldenberg DL, Pope HG Jr, et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med. 1992;92:363-367.
3. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25:285-297.
4. Wilson HD, Robinson JP, Turk DC. Toward the identification of symptom patterns in people with fibromyalgia. Arthritis Rheum. 2009;61:527-534.
5. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990;33:60-172.
6. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome-a systematic review. Eur J Pain. 2010;14:5-10.
7. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589-1594.
8. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:499-511.
9. Clauw DJ. Fibromyalgia: an overview. Am J Med. 2009;122: S3-S13.
10. Crofford LJ. Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nat Rev Rheumatol. 2010;6:191-197.
11. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol. 2008;20:246-250.
12. Harris RE, Clauw DJ, Scott DJ, et al. Decreased central m-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27:10000-10006.
13. Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health Syst Pharm. 2011;68: 1307-1319.
14. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebocontrolled study. Am J Med. 2003;114:537-545.
15. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67: 536-541.
16. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.
17. Robinson RL, Kroenke K, Mease P, et al. Burden of illness and treatment patterns for patients with fibromyalgia. Pain Med. 2012a;13:1366-1376.
18. Robinson RL, Kroenke K, Williams DA, et al. Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the REFLECTIONS∗ study. Pain Med. 2013;14:1400-1414.
19. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23: 129-138.
20. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3): 89-95.
21. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol. 1991;18:728-733.
22. Kroenke K, Spitzer R. The PHQ-9: a new depression diagnostic and severity measure. Psych Annals. 2002;32: 509-521.
23. Kroenke K, Spitzer RL, Williams JBW, et al. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32: 345-359.
24. OMalley PG, Jones DL, Feuerstein IM, et al. Lack of correlation between psychological factors and subclinical coronary artery disease. N Engl J Med. 2000;343:1298-1304.
25. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-1097.
26. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297-307.
27. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006;67:1754-1759.
28. Sarzi-Puttini P, Torta R, Marinangeli F, et al. Italian Fibromyalgia Network. Fibromyalgia syndrome: the pharmacological treatment options. Reumatismo. 2008;60(suppl 1): 50-58.
29. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004;292:2388-2395.
30. Ngian GS, Guymer EK, Littlejohn GO. The use of opioids in fibromyalgia. Int J Rheum Dis. 2011;14:6-11